Nvidia and Genentech team up to use artificial intelligence to accelerate drug discovery

Nvidia is collaborating with biotech giant Genentech to use multi-year plans to bring state-of-the-art artificial intelligence capabilities, including generative AI, to accelerate drug discovery research . Nvidia is collaborating with biotech giant Genentech, and the two companies plan to spend several years applying state-of-the-art artificial intelligence capabilities, including generative AI, to accelerate drug development

Nvidia hopes to use its generative AI models and algorithms transformed into a "next generation AI platform" to enhance Genentech's advanced AI research programs to accelerate the discovery of new treatments and drugs

Genentech plans to leverage Nvidia's expertise to significantly improve their own Developed machine learning algorithms and models. To do this, they plan to use Nvidia's DGX Cloud, a training-as-a-service platform based on Nvidia's proprietary AI hardware. DGX Cloud includes Nvidia's GPU and software such as Nvidia BioNemo

BioNeMo is now provided to users as a new platform for training services, belonging to specific fields. The platform simplifies, accelerates and scales the process of applying generative artificial intelligence to drug discovery, allowing researchers to pre-train or fine-tune state-of-the-art models on the DGX Cloud

Nvidia will collaborate with Genentech share their computing expertise. Nvidia said it will work closely with Genentech’s team of computational scientists to optimize and scale AI models and improve its own platform.

Drug discovery and development is an extremely long and complex process that, for scientists, Predicting the targets of new drugs remains extremely difficult, as does developing molecules with therapeutic potential. Genentech said that this process is still very uncertain. However, Genentech believes that AI can play a key role in making this easier. Genentech said that AI will help the drug discovery process become more predictable and cost-effective, and can improve the success rate of R&D projects in the long run.

Aviv Regev, Genentech’s executive vice president, head of research and early development, said the initiative will help his company make new scientific discoveries at an “incredible pace” and generate insights at scale. . He said: "Combining science and technology has always been the foundation of Genentech's biomedical breakthroughs, and we are pleased to join forces with Nvidia to further optimize our drug discovery and development to deliver treatments that change people's lives."

Genentech’s AI team is busy developing AI and machine learning foundation models across multiple research areas, covering diverse treatment modalities. Their goal is to gather insights into drug discovery while answering fundamental questions about human biology and disease

Rewritten content reads: Another goal of Genentech is to accelerate the advancement of its "Circular Lab" initiative, which Focus on using experimental data to inform computational models so that the models can discover patterns and make new, experimentally verifiable predictions. According to Genentech, their scientists are now able to use Nvidia’s platform to more quickly evaluate these predictions and feed the results back into their underlying computational models for improvements to develop more effective treatments.

The collaboration will leverage Genentech's proprietary data as well as publicly available data sets. Nvidia itself will not have access to Genentech's data unless it obtains special permission to use the data in a specific project.

The above is the detailed content of Nvidia and Genentech team up to use artificial intelligence to accelerate drug discovery. For more information, please follow other related articles on the PHP Chinese website!